期刊文献+

药学干预对ICU感染患者药费及临床转归的影响 被引量:7

Influence of pharmaceutical intervention on drug cost and clinical prognosis of infected patients in intensive care unit
下载PDF
导出
摘要 目的:分析临床药师对西安交通大学第二附属医院ICU感染患者的药学干预,评价药学干预对患者药费和临床转归的影响。方法:临床药师对ICU感染患者的药学干预主要包括3部分,基于临床疗效和肾毒性的药学干预、基于医疗费的药学干预及其他药学干预。具体的药学干预措施包括更换合适的抗菌药物,停用不必要的抗菌药物,停用2种及以上有肾毒性的药物,调整用药频次或用药剂量,联合使用抗菌药物,改变给药途径等。将402例本院ICU感染患者分为药学干预组(n=190)和无药学干预组(n=212),比较两组患者的药费和转归情况。结果:药学干预组患者的日均药费明显低于无药学干预组[(2220.99±734.45)元/dvs(2455.27±811.24)元/d,P=0.003],平均住院时间更短[(7.81±4.00)dvs(8.73±4.08)d,P=0.022],肾毒性药品不良反应(ADRs)发生率明显更低[5.79%(11/190)vs12.73%(27/212),P=0.019]。结论:临床药师对ICU感染患者的药学干预可以降低药费,缩短住院时间,降低肾毒性ADRs发生率,有重要临床价值。 Objective: To analyze pharmaceutical intervention by clinical pharmacists on patients in the intensive care unit(ICU) of the Second Hospital Affiliated to Xi’an Jiaotong University,and evaluate the influence of pharmaceutical intervention on drug cost and clinical prognosis.Methods:Pharmaceutical intervention by clinical pharmacists on infected patients in ICU mainly includes three types,the intervention based on clinical efficacy and nephrotoxicity,the intervention based on medical cost and other interventions.Specific interventions include replacement with appropriate antibacterials,abandoning of unnecessary antibacterials,abandoning of two or more drugs with nephrotoxicity,adjustment of medication frequency or dosages of the drugs,combined use of antibiotics,changes of administration routes,etc.402 infected patients in the ICU of the hospital were divided into the pharmaceutical intervention group( n =190) and the non-pharmaceutical intervention group( n =212).The drug cost and prognosis of infected patients were compared between the two groups. Results:The daily average drug cost of the patients in the pharmaceutical intervention group was significantly lower than that of the patients in the non-pharmaceutical intervention group [(2 220.99± 734.45) RMB/d vs (2 455.27±811.24) RMB/d,P =0.003],the average hospitalization duration was even shorter [(7.81± 4.00) d vs (8.73±4.08) d,P =0.022],and the rate of nephrotoxic adverse drug reactions(ADRs) was significantly lower [5.79%(11/190) vs 12.73%(27/212),P =0.019].Conclusion:Pharmaceutical intervention by clinical pharmacists on the infected patients in ICU could reduce drug cost,shorten hospitalization duration,lower the rate of nephrotoxic ADRs,and is of important clinical significance.
作者 王海涛 王娜 刘娜 余静洁 王春亚 赵玉杰 WANG Haitao;WANG Na;LIU Na;YU Jingjie;WANG Chunya;ZHAO Yujie(Department of Pharmacy,the Second Hospital Affiliated to Xi’an Jiaotong University,Xi’an 710004,China;Intensive Care Unit,the Second Hospital Affiliated to Xi’an Jiaotong University,Xi’an 710004,China)
出处 《药学服务与研究》 CAS 2019年第4期288-291,共4页 Pharmaceutical Care and Research
关键词 临床药师 药学干预 感染 合理用药 clinical pharmacist pharmaceutical intervention infection rational use of drugs
  • 相关文献

参考文献1

二级参考文献12

  • 1I)oan TL, Fung HB, Melata D, et al,. Tigecyeline: clycylcycline antimicrobial agent[J]. Clin Ther,2006, 28(8) : 1079-1106.
  • 2Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trail(TEST) 2005-2007[J]. Clin Ther, 2008,30 ( 11 ) : 2040-2050.
  • 3TYGACIL(tigecyeline) for injection for intravenous use initial U. S. [EB/OL]. http://www, aceessdata, fda. gov/ drugsat fda_docs/label/2013/021821 s026s031 lbl. pdf.
  • 4Clinical and Laboratory Standards Institute. Performance standards for antimierobial susceptibility testing[S]. Twenty- third infromational suplement, 2013, M100-$23.
  • 5van Duin D, Kaye KS, Nueuner EA, et al. Carbapenem resistant Enterobacteriaceae: a review of treatment and outcomes[J]. Diagn Mierobiol Infect Dis, 2013,75 (2) : 115- 120.
  • 6Andrasevic AT, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009) [J]. Int J Antimicrob Agent, 2(112,39(2) : 115-123.
  • 7Tattevin P, Cremieux AC, Rabaud C, et al. Efficacy and quality of antibacterial generic products approved fro human use a system reivew[J]. Clin Infect Dis, 2014, 58(4):458-469.
  • 8Piller CM, Draghi DC, Dowichy MJ, et al. In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and Etest[J]. J Clin Microbiol, 2008, 46(9):2862 2867.
  • 9Zarkotou O, Pourmaras S, Altouvas G, et al. Comparative evaluation of tigecycline susceptibiltiy testing methods for expanded-spectrum cephalosporimand carbapenem-resistant Gram-negative pathogens [J]. J Clin Microbiol, 2012, 5() ( 11 ) : 3747 3750.
  • 10Liu JW, Ko WC, Huang CH, et al. Agreement assessment of tigecycline susceptibility determined by the disk diffusion and broth microdiltion methods among commonly encountered resistant bacterial isolates= results from the tigecycline in Vitro Surveillance in Taiwan(TIST) study,2008 to 2010[J]. Antimicrob Agents Chemother, 2012,56(3) : 1414-1417.

共引文献7

同被引文献59

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部